

among viral strains of HIV-1 with the same envelope subtype. Evidence should include a justification for the laboratory techniques selected, documentation of either proficiency with these methods or specific plans and commitments to access services from a laboratory which has demonstrated this proficiency, and assurance that capacity is adequate to accomplish the analyses necessary for the proposed research. Letters of support from collaborating institutions or organizations should be included. (15 points)

5. Demonstration of a history of conducting comparable research studies. Research studies related to the molecular biology, genetic diversity, or genetic evolution of HIV-1 are of greatest interest. (10 points)

6. The capacity to effectively manage the study as evidenced by the proposed organizational structure, the quality and experience of proposed personnel with realistic and sufficient percentage-time commitments; clarity of the described duties and responsibilities of project personnel; adequacy of the facilities; and plans for administration of the project including project oversight and data management. Evidence should document qualifications of a prospective PI and other key personnel, and, if indicated, support arrangements with a university, community-based or other affiliated organization, etc. (15 points)

7. A comprehensive schedule, including a time line, for accomplishing the activities of the research and an evaluation plan that identifies methods and instruments for evaluating progress in designing and implementing the research objectives. (10 points)

8. Other (Not Scored).

a. Budget: The budget will be reviewed to determine the extent to which it is reasonable, clearly justified, consistent with the intended use of funds, and allowable. All budget categories should be itemized.

b. Human Subjects: Whether or not exempt from the Department of Health and Human Services (DHHS) regulations, are procedures adequate for the protection of human subjects?

H. Other Requirements

Technical Reporting Requirements

Provide CDC with original plus two copies of

1. Annual progress reports;
2. Financial status report, no more than 90 days after the end of the budget period; and
3. Final financial status and performance reports, no more than 90

days after the end of the project period. Send all reports to the Grants Management Specialist identified in the paragraph Where to Obtain Additional Information.

The following additional requirements are applicable to this program. For a complete description of each, see Attachment I in the application kit.

- AR-1 Human Subjects Requirements
- AR-2 Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research
- AR-4 HIV/AIDS Confidentiality Provisions
- AR-6 Patient Care
- AR-7 Executive Order 12372 Review
- AR-9 Paperwork Reduction Act Requirements
- AR-10 Smoke-Free Workplace Requirements
- AR-11 Healthy People 2000

I. Authority and Catalog of Federal Domestic Assistance Number

This program is authorized under Sections 301 and 311 of the Public Health Service Act, [42 U.S.C. 241 and 243], as amended. The Catalog of Federal Domestic Assistance number is 93.943.

J. Where To Obtain Additional Information

To receive additional written information and to request an application kit, call 1-888-GRANTS4 (1-888-472-6874). You will be asked to leave your name and address and to identify the Announcement number, 99105. If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from: Kevin Moore, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 2920 Brandywine Road, Room 3000, Mail Stop E-15, Atlanta, GA 30341, Telephone (770) 488-2737, E-mail address KGM1@cdc.gov.

For a detailed description of the additional requirements in Attachment 1, to download forms required by this announcement, and to review other CDC program announcements, see the CDC home page on the Internet: www.cdc.gov.

For program technical assistance, contact Kay Lawton, Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, NE., Mail Stop E-46, Atlanta, Georgia 30333, telephone (404) 639-6131, E-mail address KEL1@cdc.gov.

Dated: May 21, 1999.

John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99-13493 Filed 5-26-99; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

CDC Advisory Committee on HIV and STD Prevention: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: CDC Advisory Committee on HIV and STD Prevention.

Times and Dates: 8:30 a.m.-5 p.m., June 24, 1999; 8:30 a.m.-3 p.m., June 25, 1999.

Place: Corporate Square Office Park, Corporate Square Boulevard, Building 11, Room 1413, Atlanta, Georgia 30329.

Status: Open to the public, limited only by the space available. The meeting room will accommodate approximately 100 people.

Purpose: This Committee is charged with advising the Director, CDC, regarding objectives, strategies, and priorities for HIV and STD prevention efforts including maintaining surveillance of HIV infection, AIDS, and STDs, the epidemiologic and laboratory study of HIV/AIDS and STDs, information/education and risk reduction activities designed to prevent the spread of HIV and STDs, and other preventive measures that become available.

Matters to be Discussed: Agenda items include issues pertaining to (1) syphilis elimination (2) HIV Prevention Community Planning and (3) encouraging early diagnosis of HIV infection. Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Paulette Ford, Committee Management Analyst, National Center for HIV, STD, and TB Prevention, 1600 Clifton Road, NE, M/S E-07, Atlanta, Georgia 30333, telephone 404/639-8008, fax 404/639-8600, e-mail pbf7@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: May 21, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99-13492 Filed 5-26-99; 8:45 am]

BILLING CODE 4163-18-P